1-甲烷磺酰基哌啶-4-甲醇 | 241134-34-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 1-甲烷磺酰基哌啶-4-甲醇
• 英文名称: (1-(methylsulfonyl)piperidin-4-yl)methanol
• 英文别名: (1-methylsulfonylpiperidin-4-yl)methanol
• CAS: 241134-34-9
• 化学式: C₇H₁₅NO₃S
• 分子量: 193.267
• InChiKey: WDKWVYKURJCBFY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.4
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  66
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1-甲烷磺酰基哌啶-4-甲醇 在 Celite 、 pyridinium chlorochromate 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 生成 Piperidine, 4-(diphenylmethylene)-1-(methylsulfonyl)-
  参考文献：
  名称：

  Synthesis of diarylazepan-4-ones

  摘要：

  Synthesis of several 3,3-diarylazepan-4-ones and 5,5-diarylazepan-4-ones has been established starting from two tetrasubstituted olefins, which is derived from commercially available piperidine-3-carboxylic acid ethyl ester and piperidine-4-carboxylic acid ethyl ester. The single isomer with the structural skeleton of 3,3-diarylazepan-4-one and 5,5-diarylazepan-4-one is constructed in two functional group transformations of Grignard addition/dehydration and epoxidation/pinacol rearrangement. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2006.11.072
• 作为产物：
  描述：

  1-(甲基磺酰基)-4-哌啶羧酸乙酯 在 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 为溶剂， 反应 10.0h， 以69%的产率得到1-甲烷磺酰基哌啶-4-甲醇
  参考文献：
  名称：

  [EN] KINASE ANTAGONISTS AND METHODS FOR MAKING AND USING THEM
  [FR] ANTAGONISTES DES KINASES, PROCÉDÉS DE FABRICATION ET D'UTILISATION ASSOCIÉS

  摘要：

  本文披露了一种小分子化合物，它们是SGK1拮抗剂，包括这些化合物的配方和药物组合物，以及制备和使用它们的方法，用于治疗、改善、预防、逆转或减缓以下疾病的进展：癌症、肿瘤、转移瘤或对AGC激酶群中包括SGK1的激酶酶的抑制有反应的异型增生或功能异常细胞状况，通过给予AGC激酶抑制剂或拮抗剂。

  公开号：

  WO2020023393A1

文献信息

• [EN] CYP11A1 INHIBITORS<br/>[FR] INHIBITEURS DE CYP11A1
  申请人：ORION CORP

  公开号：WO2021229152A1

  公开（公告）日：2021-11-18

  The present invention relates to a compound of formula (I) or (II) wherein R1, R2, R3, R4, R5, R23, R24, R25, R26, R27, L, A and B are as defined in claim 1, or pharmaceutically acceptable salts thereof are disclosed. The compounds of formula (I) or (II) possess utility as cytochrome P450 monooxygenase 11A1 (CYP11A1) inhibitors. The compounds are useful as medicaments in the treatment of steroid receptor, particularly androgen receptor, dependent diseases and conditions, such as prostate cancer.

  本发明涉及一种具有式（I）或（II）的化合物，其中R1、R2、R3、R4、R5、R23、R24、R25、R26、R27、L、A和B如权利要求书中所定义，或其药学上可接受的盐。式（I）或（II）的化合物具有作为细胞色素P450单加氧酶11A1（CYP11A1）抑制剂的效用。这些化合物在治疗类固醇受体，特别是雄激素受体依赖性疾病和症状，如前列腺癌中作为药物是有用的。
• 2-arylethyl-(piperidin-4-ylmethyl)amine derivatives
  申请人：Syntex (U.S.A.) LLC

  公开号：US06319920B1

  公开（公告）日：2001-11-20

  This invention relates to muscarinic receptor antagonist compounds selected from the group of compounds represented by Formula I: wherein the substituents are as defined in the specification; and their pharmaceutically acceptable salts, individual isomers or a racemic or non-racemic mixture; pharmaceutical compositions containing them; and methods for their use as therapeutic agents.

  这项发明涉及从由化学式I代表的化合物组中选择的肌氨酸受体拮抗剂化合物；其中取代基如规范中定义；以及它们的药学上可接受的盐、单体异构体或拉式或非拉式混合物；含有它们的药物组合物；以及它们作为治疗剂的使用方法。
• IMIDAZOPYRIDIN-2-ONE DERIVATIVES
  申请人：Ohtsuka Masami

  公开号：US20110082138A1

  公开（公告）日：2011-04-07

  A compound represented by formula (I) having mTOR inhibitory activity or a pharmacologically acceptable salt thereof.

  具有mTOR抑制活性的公式(I)表示的化合物或其药理可接受的盐。
• Fused-ring compounds and use thereof as drugs
  申请人：Japan Tobacco Inc.

  公开号：US20030050320A1

  公开（公告）日：2003-03-13

  The present invention provides a fused ring compound of the following formula [I] 1 wherein each symbol is as defined in the specification, a pharmaceutically acceptable salt thereof, and a therapeutic agent for hepatitis C, which contains this compound. The compound of the present invention shows an anti-hapatitis C virus (HCV) action based on the HCV polymerase inhibitory activity, and is useful as a therapeutic agent or prophylactic agent for hepatitis C.

  本发明提供了以下式子的融合环化合物I1，其中每个符号如规范所定义，其药用盐，以及包含该化合物的治疗丙型肝炎的治疗剂。本发明的化合物显示出基于HCV聚合酶抑制活性的抗丙型肝炎病毒（HCV）作用，并且可用作治疗或预防丙型肝炎的药物。
• [EN] PYRAZOLOPYRIDINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE<br/>[FR] COMPOSÉS INHIBITEURS DE PI3K DE TYPE PYRAZOLOPYRIDINE ET LEURS PROCÉDÉS D'UTILISATION
  申请人：GENENTECH INC

  公开号：WO2010059788A1

  公开（公告）日：2010-05-27

  Compounds of Formula (I), and including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting lipid kinases including p110 alpha and other isoforms of PI3K, and for treating disorders such as cancer or inflammation mediated by lipid kinases. Methods of using compounds of Formula (I) for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

  公式(I)的化合物，包括立体异构体、几何异构体、互变异构体、溶剂合物、代谢产物及其药用盐，用于抑制脂质激酶包括p110α和PI3K的其他同系物，并用于治疗由脂质激酶介导的癌症或炎症等疾病。公开了使用公式(I)的化合物在哺乳动物细胞中进行体外、体内和体内诊断、预防或治疗此类疾病，或相关病理状况的方法。